Looking for another solid quarter from the company that sets the Gold Standard for the industry. In addition to more phase III compounds, will they announce an initiative into the Nanotechnology area? It is also some time since we heard about the reverse engineered Generics that were to be manufactured at Organichem. As Biotechnology has been seeing some positive forward movement I am looking for revenues in the contract area to have increased significantly......Thoughts?
I am going to skip your string of nanotechnology-gold standards-phaseIII�.. 1000th edition, not worth it� it is very surprising to me that no-one, yahoo or AMRI, hasn't taken any action (legal for AMRI) against you, for posting on this board about earnings. You publicly claim to be an insider and still dare to post earning opinions before their official release�I just don�t get it� are you that high to be untouchable in this company????????
I also think we will see them up significantly, and I wouldn't be surprised if company raises its earnings guidance once again. The only question mark might be the Allegra royalties, but my best guess is that they will come in around $15 million to $16 million and the forward guidance for this revenue stream will be flat to slightly above what company received in '05.